Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid

Clin Lung Cancer. 2021 May;22(3):e442-e445. doi: 10.1016/j.cllc.2020.06.011. Epub 2020 Jun 18.

¹ Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
² Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
³ Division of Surgical Pathology, Department of Pathology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
⁴ Division of Neuro-Oncology, Department of Neurology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
⁵ Loxo Oncology, Inc, a whole owned subsidiary of Eli Lilly & Co, Stamford, CT.
⁶ Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH. Electronic address: bhavana.konda@osumc.edu.

No abstract available

Keywords: Atypical lung carcinoid; Neuroendocrine tumor; RET; RET fusion; Targeted therapeutics.

Publication types